PolyNovo (ASX:PNV) has announced that Professor Toby Coates AO, the director of Beta Cell Technologies, has presented the results of the company's NovoSorb and its potential role in treating and managing Type 1 diabetes.
-
Latest News
CSL Behring wins major international pharmaceutical engineering award
May 14, 2025 -
Latest News
Immutep’s efti with PD-L1 and chemotherapy achieves high response rates in lung cancer
May 14, 2025 -
Latest News
Amplia reports updated positive data from ACCENT trial in pancreatic cancer
May 14, 2025
-
Latest News PolyNovo's NovoSorb BTM delivers positive first in human results in diabetes May 14, 2025
-
Latest News Lumos advances FebriDx sales with iMedical purchase order May 14, 2025Point-of-care diagnostic technology company Lumos Diagnostics (ASX:LDX) states that it has received a purchase order and shipped the product for FebriDx to iMedical.
-
Latest News Australia gets a new minister for industry, innovation and science May 12, 2025Prime Minister Anthony Albanese has appointed Senator Tim Ayres to the industry, innovation and science portfolios.
-
Latest News EnGeneIC launches groundbreaking new Australian trial for innovative cancer therapy May 12, 2025EnGeneIC has announced the dosing of the first patient in its open-label, multicentre, Phase I/IIa clinical trial at Mater Hospital in Sydney.
-
Latest News PolyNovo announces TGA clearance for NovoSorb MTX and enters trading halt May 12, 2025PolyNovo (ASX:PNV) has announced that its NovoSorb MTX (4 mm, 6 mm) has received TGA clearance, following the regulator's clearance of the 2 mm product in March.
-
Latest News Monash scientists secure MRFF funding to find new medicines for dementia by 'lighting up' human brain cells May 12, 2025A team of Melbourne scientists has been backed by the Australian Government’s Medical Research Future Fund Stem Cell Therapies Mission to support their development of potential new medicines to treat dementia.
-
Latest News Radiopharm Theranostics accelerates 177Lu-RAD204 Phase 1 dose escalation trial May 12, 2025Radiopharm Theranostics (ASX:RAD) has achieved a milestone in its ongoing clinical development program for its radiotherapeutic asset, 177Lu-RAD204.
-
Latest News Experienced industry executive appointed chair of Tryptamine Therapeutics May 12, 2025Clinical-stage company Tryptamine Therapeutics (ASX:TYP) has announced the appointment of Herwig Janssen as its non-executive chairman.
-
Latest News OncoSil Medical reports positive results of pancreatic cancer analysis May 7, 2025OncoSil Medical managing director and CEO Nigel Lange said, “The results of this important analysis highlight the superiority of the OncoSil device compared to Stereotactic Body Radiation Therapy, which is considered to be the best available system for delivering external beam radiotherapy to patients with locally advanced pancreatic cancer."
-
Latest News Percheron Therapeutics launches bonus loyalty option offer May 7, 2025Percheron Therapeutics (ASX:PER) has lodged a prospectus for a pro-rata non-renounceable bonus offer of unquoted options to acquire loyalty options to eligible shareholders.
-
Latest News Neuren updates on first quarter 2025 US sales of Daybue May 7, 2025Neuren Pharmaceuticals (ASX:NEU) has updated investors on the first quarter 2025 financial results announcement and conference call of its partner Acadia Pharmaceuticals.
-
Latest News Algorae Pharmaceuticals partners with Peter Mac for AI-driven drug synergy screening May 7, 2025Algorae Pharmaceuticals (ASX:1AI) has agreed with the Victorian Centre for Functional Genomics at Peter MacCallum Cancer Centre to validate AI-predicted drug synergies through high-throughput screening.
-
Latest News LTR Pharma signs agreement to co-develop novel intranasal spray for Oesophageal Motility Disorders May 7, 2025LTR Pharma (ASX:LTP) has entered a collaborative development agreement with Strategic Drug Solutions to co-develop OROFLOW, a novel intranasal spray targeting Oesophageal Motility Disorders.
-
Latest News Medtech investment event unites investors and innovators to boost sector growth May 5, 2025AusBiotech CEO Rebekah Cassidy said the investor-focused event will help accelerate the delivery of real-world, home-grown health solutions.
-
Latest News Positive trial result for Immutep’s 'efti' in combination with MSD's anti-PD-1 therapy May 5, 2025Immutep (ASX:IMM) has announced positive results from a Phase 2b trial of its eftilagimod alfa (efti) in combination with MSD's KEYTRUDA (pembrolizumab) for head and neck cancer.
-
Latest News AusBiotech and ANDHealth partner to foster sector connection in digital health May 5, 2025AusBiotech has signed a partnership agreement with digital health commercialisation specialist ANDHealth to enhance collaboration on mutual interests and support ongoing industry innovation.
-
Latest News FDA grants fast track designation for Alterity's ATH434 to treat multiple system atrophy May 5, 2025Alterity Therapeutics (ASX:ATH) has announced that the US FDA has granted fast track designation for ATH434 for treating Multiple System Atrophy.
New Stories
-
PolyNovo's NovoSorb BTM delivers positive first in human results in diabetes
May 14, 2025 - - AusBiotech -
Amplia reports updated positive data from ACCENT trial in pancreatic cancer
May 14, 2025 - - Latest News -
Immutep’s efti with PD-L1 and chemotherapy achieves high response rates in lung cancer
May 14, 2025 - - Latest News -
CSL Behring wins major international pharmaceutical engineering award
May 14, 2025 - - Latest News -
Lumos advances FebriDx sales with iMedical purchase order
May 14, 2025 - - Latest News -
PolyNovo's NovoSorb BTM delivers positive first in human results in diabetes
May 14, 2025 - - Latest News -
EnGeneIC launches groundbreaking new Australian trial for innovative cancer therapy
May 12, 2025 - - Latest News